Global Patent Index - EP 2637644 A1

EP 2637644 A1 2013-09-18 - LISURIDE, TERGURIDE AND DERIVATIVES THEREOF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF FIBROTIC CHANGES

Title (en)

LISURIDE, TERGURIDE AND DERIVATIVES THEREOF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF FIBROTIC CHANGES

Title (de)

LISURID, TERGURID UND DERIVATE DAVON ZUR VERWENDUNG IN DER PROPHYLAXE UND/ODER THERAPIE FIBROTISCHER VERÄNDERUNGEN

Title (fr)

LISURIDE, TERGURIDE ET LEURS DÉRIVÉS POUR UNE UTILISATION DANS LA PROPHYLAXIE ET/OU LA THÉRAPIE DE MODIFICATIONS FIBREUSES

Publication

EP 2637644 A1 (DE)

Application

EP 11781511 A

Priority

  • EP 11075179 A
  • DE 102010051391 A
  • EP 2011069480 W
  • EP 11781511 A

Abstract (en)

[origin: WO2012062676A1] The present invention relates to the use of 5-HT2 receptor antagonists and in particular of 8-a-ergolines such as lisuride, terguride and the derivatives thereof as 5-HT2B and 5-HT2A receptor antagonists and antioxidants in preferably higher-dosed and preferably continuous use for the treatment, progression prophylaxis and general prophylaxis of organ fibroses and other pathological organ remodeling caused by mesenchymal proliferation.

IPC 8 full level (invention and additional information)

A61K 9/19 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/48 (2006.01); A61P 9/12 (2006.01)

CPC (invention and additional information)

A61K 31/437 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/19 (2013.01); A61K 9/7061 (2013.01); A61K 31/48 (2013.01); A61K 45/06 (2013.01); C07D 457/12 (2013.01)

Combination set (CPC)

A61K 31/48 + A61K 2300/00

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

EPO simple patent family

WO 2012062676 A1 20120518; AU 2011328299 A1 20130704; CA 2834882 A1 20120518; CN 103476402 A 20131225; EP 2637644 A1 20130918; JP 2014501710 A 20140123; RU 2013126522 A 20141220; US 2014058108 A1 20140227; US 2015072939 A1 20150312

INPADOC legal status


2016-06-08 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20160510

2014-04-23 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: SINOXA PHARMA GMBH

2014-02-19 [DAX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT (TO ANY COUNTRY) DELETED

2013-09-18 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20130513

2013-09-18 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR